RadNet
This is the archived full research. Read the story
The biggest chain of outpatient scan centres in America: 442 places to get an MRI, CT or mammogram for less than a hospital charges.
The scores
Growth3/4 →
Revenue grew 22.1% and same-centre advanced scans 8.9% in Q3 2026, but much of the total was bought, with acquisitions every year.
Business quality3/4 →
Regional scale and a lower price than hospitals take share, but hospitals, private chains and dozens of AI rivals compete directly.
Financial position3/4 →
Net debt about $616M, 1.8 times EBITDA, term loans due 2031 and an undrawn revolver; acquisitions use more than free cash.
Execution record3/4 →
Beat and raised imaging guidance through 2025 and three times in 2026, but on adjusted figures while GAAP earnings stayed near zero.
Per share capture2/4 →
Shares up 47% since 2021 through offerings and an all-stock deal; revenue per share grew 17% while revenue grew 73%.
Potential3/4 ↑
A bounded upside on observable steps: scans shifting from hospitals, joint ventures signed, and a CMS rule pending that would help.
Risk profile3/4 →
One serious dependency, payer rates set by CMS and insurers, plus an 81-year-old founder and over 100 centres in California.
Valuation1/4 →
About 26.9 times operating profit before depreciation, 1202% of a three-stage value near $6.52 at 8%: priced for perfection, beyond the 20% margin.
Evidence quality3/4 →
Results, payer mix and debt are filed and the price gap measured by CMS; the share shift and AI benefits are inferred or management's word.
If it works 0.8× · if it fails you keep about 63%.
The Verdict
We rate RadNet Unattractive. Insurers pay its imaging centres far less than a hospital for the same scan, so patients keep moving to it, and advanced scans at existing centres grow about 9% a year: the business is solid. But growth has not yet made it more profitable, Medicare may pay less and the margin gain from AI is unproven. At about 18 times yearly earnings before interest, tax and depreciation, the price sits far above our value and our best case. As a bet on its AI software it is priced for success: about three-fifths kept if it fails.
The long caseRadiologists are scarce and scans keep growing, so software that reads images and drafts reports could sell widely, starting in RadNet's own centres.
How we weighed it
The price against our value
Against it
Price at 1202% of our value
The price sits far above our value and above the bull case.
The business
In its favour
Solid
A solid business that wins patients on price.
Growth against what the price assumes
In its favour
Patients keep coming and the yearly forecast rose again.
What could go wrong
Against it
Medicare may pay less, hospitals may compete on price and the AI plan is unproven.
Against competitors
Cuts both ways
No filed rival compares directly; against its own normal it is far dearer.
How its group is behaving
Cuts both ways
It sits in none of our ranked groups; health reimbursement moves it.
The latest news and report
Cuts both ways
The last report confirmed growth, with too small a margin gain.
The evidence under this - 8 claims
- The rule text has not been read: management summarised it on the call, and the transcript's release date (14 November) falls after the call.
- Hospitals may seek a court or congressional delay; this thesis lists that as an open risk.
- 2026-11-10editedManagement said on the 9 November call that CMS finalised the site-neutral provision; the rule text itself is not yet read
No body publishes the outpatient share of scans by year, so the shift is inferred; part of the growth is new demand, such as prostate and amyloid PET scans, now over 25% of RadNet's PET volume.
Adjusted EBITDA leaves out $59.3M of trailing stock pay, and partners' minority stakes, $298.0M at book, would add to the value; both make the multiple higher, not lower.
- 2026-11-09editedre-struck on the 6 November close and the Q3 trailing figures; the multiple after pay in shares is added under the valuation rules
- 2026-11-10editedRe-struck at the 9 November close of $78.38 and the 10-Q's share count and debt
Imaging software, the part of the segment not bought recently, still grew 17.3% in Q2 2026 (C11).
The company
When a doctor orders an MRI, a CT scan or a mammogram, the patient can usually go to a hospital or to a standalone centre. RadNet runs 442 of those centres, clustered in California, New York, New Jersey, Maryland and a few other states, and says it is the largest such chain in the country.
MRI and CT are most of the money: MRI alone brought 37.7% of its imaging payments in 2025. Its contracted radiologists read the images, and the report goes back to the doctor.
The evidence under this - 4 claims
Its same-centre margin barely moved in Q2 2026 (C04) and capitation revenue has fallen two years running (C02), neither what a widening scale advantage would show.
- The rule text has not been read: management summarised it on the call, and the transcript's release date (14 November) falls after the call.
- Hospitals may seek a court or congressional delay; this thesis lists that as an open risk.
- 2026-11-10editedManagement said on the 9 November call that CMS finalised the site-neutral provision; the rule text itself is not yet read
How it makes money
RadNet is paid per scan, mostly by private insurers ($1.13B of 2025's $2.04B revenue) and Medicare ($477M). Some health plans instead pay a fixed monthly fee per member, whatever the number of scans.
A complex scan pays much more than an X-ray, so growth in MRI, CT and PET is what lifts revenue. A small software arm also sells imaging and AI programs to hospitals.
The evidence under this - 3 claims
Where the money comes from, stream by stream
| Stream | Share of sales (FY 2025) | How it earns it |
|---|---|---|
| Commercial insurance | 55.4% | Scans paid by private insurers under negotiated contracts. |
| Medicare and Medicaid | 25.9% | Scans paid at government fee-schedule rates. |
| Capitation | 6.2% | A fixed monthly fee per member from health plans and medical groups, whatever the number of scans. |
| Other payers and fees | 12.5% | Workers' compensation, personal injury, other payers, management fees and other revenue, including Digital Health's outside sales. |
Who runs it
Howard Berger, 81, has run RadNet since 1992 and built it by buying chains and partnering with hospitals. He owns under 1% of the shares, and all directors and officers together about 5%. Doctors' groups owned by senior managers staff centres in six states.
Pay rewards staying more than results: 2025 bonuses were set at the board's discretion and long-term awards are shares that vest with time. Insiders have sold, not bought, this year.
The evidence under this - 3 claims
Why it wins, and who could beat it
Why customers come back
The edge is price and density. Medicare's own figures show a hospital department paid about $106 for a bone-density scan an office does for about $30, so insurers prefer the cheaper centre, and RadNet has the most centres where it operates.
The evidence it works: scans at its existing centres grew 9.6% in Q2 2026, while CT use across the country is growing only slowly. That gap means it is taking work from hospitals.
The evidence under this - 5 claims
- The rule text has not been read: management summarised it on the call, and the transcript's release date (14 November) falls after the call.
- Hospitals may seek a court or congressional delay; this thesis lists that as an open risk.
- 2026-11-10editedManagement said on the 9 November call that CMS finalised the site-neutral provision; the rule text itself is not yet read
No body publishes the outpatient share of scans by year, so the shift is inferred; part of the growth is new demand, such as prostate and amyloid PET scans, now over 25% of RadNet's PET volume.
- 2026-11-09editedQ3 2026 print replaces the Q2 figures: same-centre advanced scans slowed from 9.6% to 8.9%
Its same-centre margin barely moved in Q2 2026 (C04) and capitation revenue has fallen two years running (C02), neither what a widening scale advantage would show.
The threat
Hospitals still do most scans and can open centres of their own; HCA lists imaging centres among its rivals. Private chains such as SimonMed, with more than 170 locations, chase the same patients. In software, the FDA has cleared over 1,200 radiology AI products, so RadNet's AI arm sells into a crowded field.
The evidence under this - 4 claims
The rivals: HCA, GEHC, and 3 more that are private, in-house or listed abroad.
Who else does this, rival by rival
| Ticker | Rival | Where it competes | How far along | Priced against it |
|---|---|---|---|---|
| Private | SimonMedPriced against it: Private | Imaging Centers | On sale | Private |
| HCA | Hospital outpatient departments, such as HCA'sPriced against it: One segment only | Imaging Centers | On sale | One segment only |
| Private | Other private-equity-backed imaging chainsPriced against it: Private | Imaging Centers | On sale | Private |
| GEHC | GE HealthCare and LunitPriced against it: One segment only | Digital Health | On sale | One segment only |
| Private | Aidoc and TherapixelPriced against it: Private | Digital Health | On sale | Private |
How big it could get
How big this could get
Americans had about 93 million CT scans in 2023, and RadNet did about 1.2 million of them, near 1.3%. CT use is growing slowly, so the room is in taking scans from hospitals rather than in the market growing.
Nobody this search could read counts MRI or PET scans by where they are done, so the full market cannot be sized from outside.
The evidence under this - 3 claims
- The rule text has not been read: management summarised it on the call, and the transcript's release date (14 November) falls after the call.
- Hospitals may seek a court or congressional delay; this thesis lists that as an open risk.
- 2026-11-10editedManagement said on the 9 November call that CMS finalised the site-neutral provision; the rule text itself is not yet read
Who has signed
Most revenue is scan by scan, with nothing signed in advance. The firmer parts: 157 centres run as joint ventures with hospital systems, health plans paying fixed fees worth $125.5M in 2025, and about $37M of software contracts signed in the first half of 2026.
The evidence under this - 3 claims
The results
The numbers
Sales grew 21% over the twelve months to Sep 2026, faster than the 12% in the year to Dec 2025.
Operating margin is 3.1%, down from 6.1% in the year to Dec 2023.
Yearly sales growth has ranged from +8.7% to +23% over the last 5 years.
Each dollar put into the business earns 1.9% a year after tax, down from 6.9% in the year to Dec 2021.
It turned 4.8% of sales into free cash, $115M over the last twelve months.
It owes $575M more than the cash it holds, about 1.7 years of the cash its operations bring in.
The share count rose 48% in 4.8 years, and pay in shares costs 2.5% of sales.
All the numbers
Filed figures from the company's 10-K and 10-Q, read 2026-11-10. Fiscal years end in December.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | 12 mo to Sep 2026 | |
|---|---|---|---|---|---|---|
| Size and growth | ||||||
| Sales | $1.32B | $1.43B | $1.62B | $1.83B | $2.04B | $2.38B |
| Sales growth | +23% | +8.7% | +13% | +13% | +12% | +21% |
| Profit | ||||||
| Operating margin | 6.3% | 3.2% | 6.1% | 5.7% | 3.0% | 3.1% |
| Net margin | 1.9% | 0.7% | 0.2% | 0.2% | −0.9% | −0.9% |
| What growth costs, per sales dollar | ||||||
| Pay in shares | 1.9% | 1.7% | 1.7% | 1.6% | 2.7% | 2.5% |
| Capital spending | 10% | 8.4% | 11% | 10% | 10% | 9.8% |
| Cash | ||||||
| Cash from operations | $149M | $146M | $221M | $233M | $299M | $348M |
| Free cash flow | $11.6M | $27.0M | $44.3M | $45.0M | $85.6M | $115M |
| Balance sheet | ||||||
| Cash and short-term investments | $135M | $128M | $343M | $740M | $767M | $751M |
| Debt | $755M | $852M | $830M | $1.02B | $1.09B | $1.33B |
| Net cash | −$620M | −$724M | −$487M | −$276M | −$323M | −$575M |
| Returns and shares | ||||||
| Return on capital | 6.9% | 3.3% | 5.8% | 5.4% | 1.6% | 1.9% |
| Shares (diluted) | 53.4M | 57.3M | 64.7M | 74.8M | 75.2M | 79.2M |
What growth costs
Growth has not made RadNet more profitable. Revenue rose by more than half from 2021 to 2025 while operating profit fell, pay in shares doubled, and capital spending on centres and scanners now takes most of the cash the business brings in.
The evidence under this - 2 claims
The last report (8 Nov)
Quarter ended September 2026, filed figures.
The September 2026 quarter was RadNet's biggest yet. Revenue rose 22.1% to $638.3M and earnings before interest, tax and depreciation, its main measure, 23.8% to $105.0M. Management raised its yearly forecast for the third time.
The margin moved only a little: 16.5% of each revenue dollar, against 16.2% a year earlier. Advanced scans at centres open a year rose 8.9%, a touch under the pace we watch. Management said a raised forecast just adds the quarter's beat.
Final Medicare rates cost about $5M of 2027 revenue, and management said the final hospital rule pays hospitals less for some scans.
What it did to the thesisIt confirmed the growth half of the argument again: patients keep coming and the forecast rose. The margin gain was too small to answer the half the price needs, so whether growth ever makes the business more profitable stays open.
The quarter in detail
Sales growth from the previous quarter, filed figures.
Earnings per share $0.30 against $0.22 expected.
The evidence under this - 6 claims
- 2026-11-09editedQ3 2026 print replaces the Q2 figures
- 2026-11-09editedQ3 2026 print replaces the Q2 figures: same-centre advanced scans slowed from 9.6% to 8.9%
Q1 was cut by about $9M of adjusted EBITDA by weather (C33), so the full year needs a second half of $186M to $199M of imaging adjusted EBITDA, the strongest half the company has reported.
- 2026-11-09editedthird raise at Q3 2026 replaces the Q2 guidance
- The first half carried Florida's integration costs and $9M of weather, which management says will not recur; a seasonal second half has been stronger before.
- On the 9 November call the chief financial officer said that when guidance is amended the company adds the quarter's beat and does not reforecast the rest of the year, that the trends continued into early November, and that the fourth quarter has been the strongest for several years; the implied $88.9M to $101.9M is a floor of method, not a prediction.
- 2026-11-09editedQ3 2026 beat the quarter the Q2 guidance implied; the guidance now implies a fourth quarter below Q3
- 2026-11-10editedThe call explained how the guidance was raised: management adds the quarter's beat and does not reforecast, so the implied fourth quarter is not a forecast
- Digital Health made $3.0M of adjusted EBITDA in the quarter against $3.5M a year earlier, on $32.9M of revenue, and 31% of the AI revenue is the Gleamer purchase.
- The ONRAD figures are the company's expectations for a business it does not yet own; the deal is expected to close in early 2027.
The rule is a proposal; the final rule is due in November 2026, and RadNet's 10-K says rate cuts reduce revenue unless volumes or mix make up for them.
- 2026-11-10editedManagement priced the final rule on the 9 November call at about $5M of 2027 revenue, up from under $1M
What management did with the money
Management spends the cash on new centres, scanners and acquisitions. In the first half of 2026 it paid $315.7M for businesses, including a French AI firm, and borrowed $248.9M more. Earlier deals were paid with new shares, which is why each share owns less of the company than in 2021.
Insiders in 2026Q2: 5 purchases and 5 sales, from their Form 4 filings.
The evidence under this - 3 claims
The price, and where we disagree
In short. Priced for perfection. The price is about 1202% of what we think the business is worth, at an 8% yearly return.
The shares have swung hard: from near $80 last November to $50.82 in June and to $76.00 after three raised forecasts.
The September-quarter results beat the quarter the last forecast implied; the fourth quarter and the ONRAD closing are the next tests, and Medicare's final 2027 rules follow. On 26 October RadNet agreed to buy teleradiology firm ONRAD for $350M in cash and 5M shares; the profit it claims for it is unchecked.
The evidence under this - 6 claims
- 2026-11-09editedre-struck on the 6 November close with a fresh research pack
Q1 was cut by about $9M of adjusted EBITDA by weather (C33), so the full year needs a second half of $186M to $199M of imaging adjusted EBITDA, the strongest half the company has reported.
- 2026-11-09editedthird raise at Q3 2026 replaces the Q2 guidance
- The rule text has not been read: management summarised it on the call, and the transcript's release date (14 November) falls after the call.
- Hospitals may seek a court or congressional delay; this thesis lists that as an open risk.
- 2026-11-10editedManagement said on the 9 November call that CMS finalised the site-neutral provision; the rule text itself is not yet read
Management's own summary of a rule released five days earlier; the CMS document has not been read, and Congress has reversed part of such cuts before, which would help RadNet.
- 2026-11-10editedManagement gave the final conversion factor on the 9 November call
Imaging adjusted EBITDA margin is about 16%, so a business RadNet describes as earning about a third of its revenue as adjusted EBITDA is a different kind of profit pool, and the figure is unaudited and unchecked by any outside party.
How we value it
- Method
- Cash the business will produce, in three stages
- Required return
- 8%
- Long-run growth
- 4%
- Moat
- An average moat
| Bear | Base | Bull | |
|---|---|---|---|
| Sales growth, years 1 to 3 | 7.5%, 5% | 15.1%, 9.9% | 18.9%, 12.4% |
| Normal operating margin | 2.6% | 3.2% | 3.5% |
| Return on new capital after year ten | 8% | 12% | 15% |
| Value a share | $0.66 | $6.52 | $10.50 |
- Price
- $78.38
- Priced on
- 9 Nov
- Price as a share of the base value
- 1202%
- Yearly return the price offers on the base case
- 4.7%
- Risk check: valued at 10%, the rate for a cyclical or indebted business
- $1.16
Where each figure comes from
| Figure | Source | Where exactly |
|---|---|---|
| Sales, the last twelve months | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the four quarters to that date. |
| Operating margin today | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the four quarters to that date. |
| Tax rate | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the four quarters to that date. |
| Sales per dollar of new capital | Filed report | Annual report (10-K) for the period to 31 Dec 2025, filed 2 Mar 2026: the year's sales over its operating capital. |
| Shares | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the diluted share count. |
| Cash and investments | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the balance sheet on that date. |
| Debt | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the balance sheet on that date. |
| Sales growth, years 1 to 3 | Analysts' forecasts | FMP's consensus for the years to 31 Dec 2026, 31 Dec 2027 and 31 Dec 2028: the average of 3 to 4 analysts' revenue estimates, 15.8%, 10.5%. FMP publishes how many analysts, not who they are. |
| Normal operating margin | Analysts' forecasts | FMP's consensus operating margin for the year to 31 Dec 2028, the average of 4 analysts' estimates, 5.7%, less stock pay of 2.5% of sales. FMP publishes how many analysts, not who they are. |
| Return on new capital after year ten | Our method's rule | Set by our reading of the moat: the 8% rate with none, 12% with an average one, 15% with a strong one; the bear case earns the rate. |
| The bear and bull cases | Our method's rule | Our method's spread: the bear case takes half the growth and a fifth off the margin, the bull a quarter more growth and a tenth more margin. |
| Price | Market price | FMP's closing price on 9 Nov 2026. |
What each case rests on
Bear caseGrowth runs at half the analysts' path, 8% and 5%, the margin settles a fifth lower at 2.6%, and new capital earns only the 8% rate: the downturn test.
Base caseRevenue grows 15% and 10% over three years, the analysts' path (C43) measured from the twelve months to September, then fades toward 4%, closing 30% of the gap each year; the margin moves to 3.2%, the analysts' year-three figure after stock pay.
Bull caseGrowth runs a quarter above the analysts' path, 19% and 12%, the margin reaches 3.5%, and new capital earns 15%.
What moves the base value
| Lower | Higher | |
|---|---|---|
| Growth in years 1 to 3, a quarter lower or higher | $5.86 | $7.23 |
| The normal margin, 15% lower or higher | $4.06 | $8.98 |
| Capital per dollar of growth, a quarter more or less | $5.15 | $7.34 |
| Return on new capital after year ten, at the rate or one step up | $3.30 | $7.81 |
| The rate, a point higher or lower | $3.29 | $11.95 |
| Long-run growth a point lower | $5.02 | - |
Value a share as growth and margin change
| Normal margin ↓ · growth → | 50% | 75% | 100% | 125% | 150% |
|---|---|---|---|---|---|
| 2.6% | $2.58 | $2.90 | $3.25 | $3.62 | $4.04 |
| 2.9% | $3.92 | $4.38 | $4.88 | $5.43 | $6.02 |
| 3.2% | $5.26 | $5.86 | $6.52 | $7.23 | $8.00 |
| 3.5% | $6.60 | $7.35 | $8.16 | $9.04 | $9.99 |
| 3.8% | $7.94 | $8.83 | $9.79 | $10.84 | $11.97 |
Growth is shown as a share of the base case's. Green: the price is at or under 80% of that value. Red: at or over 120%.
How we read the multiple
A buyer pays for years of growth and rising margins.
1. The shares are worth about $6.2B; with about $575M of net debt the business is valued at about $6.8B. 2. It earned $355.7M before interest, tax and depreciation over the past year, on its own measure, which leaves out pay in shares. 3. So the business costs about 19 times those earnings, and about 23 times after pay in shares. 4. Free cash flow this year is forecast at about $107M, under 2% of the shares' value.
Against its own history. Buyers pay well above the company's usual price for each dollar of earnings, for growth that has not yet made the business more profitable.
The evidence under this - 3 claims
Adjusted EBITDA leaves out $59.3M of trailing stock pay, and partners' minority stakes, $298.0M at book, would add to the value; both make the multiple higher, not lower.
- 2026-11-09editedre-struck on the 6 November close and the Q3 trailing figures; the multiple after pay in shares is added under the valuation rules
- 2026-11-10editedRe-struck at the 9 November close of $78.38 and the 10-Q's share count and debt
- 2026-11-09editedre-struck on the 6 November close
Priced against its rivals
None of the listed rivals above sells the same thing to the same buyers as a large part of what it does. A price comparison needs at least two, so the price is judged against its own history instead.
The bet: what it pays if it works
The bet is on Digital Health, the software and AI that read scans. It loses money and most of its recent growth was bought, so the imaging centres are counted separately, at the price this thesis would call fair.
If the software keeps growing about a fifth a year, the shares end up worth less than today, because the price already pays far more for it than that is worth. If it never earns, shareholders keep the centres, about three-fifths of today's value.
| Digital Health revenue in two to three years | Customers at today's recurring revenue each needed | At the stated multiple |
|---|---|---|
| $140.00M | about 3.8K at 100% kept | 0.8× |
| $200.00M (the big win) | about 5.4K at 100% kept | 0.8× |
| $280.00M | about 7.6K at 100% kept | 0.9× |
To pay 2× (a Fair bet) it would need about $2.45B of Digital Health revenue (about 66.3K customers at today's recurring revenue each); to pay 5× (a Cheap bet), about $8.15B of Digital Health revenue (about 220.4K customers at today's recurring revenue each), at the same multiple.
Each row is Digital Health alone, plus the rest of the company (Imaging Centers) counted at about $4.99B.
The steps it has to take
- Done Breast-screening AI in use across RadNet's centres
- Done iCAD and Gleamer bought and folded into Digital Health
- In progress Digital Health recurring revenue above $140M due 2026-12
- Not started AI drafting half of RadNet's reports due 2027-06
- Not started Digital Health profitable after research spending due 2027-12
- Not started Digital Health margin above 20% due 2028-12
The detail behind the label
The evidence under this - 6 claims
Imaging margins rose only 0.17 points in Q2 2026 despite a 2.4-point shift toward advanced scans; management blamed salary inflation and the cost of rolling out its own AI (C36).
Imaging software, the part of the segment not bought recently, still grew 17.3% in Q2 2026 (C11).
Q1 was cut by about $9M of adjusted EBITDA by weather (C33), so the full year needs a second half of $186M to $199M of imaging adjusted EBITDA, the strongest half the company has reported.
- 2026-11-09editedthird raise at Q3 2026 replaces the Q2 guidance
Adjusted EBITDA leaves out $59.3M of trailing stock pay, and partners' minority stakes, $298.0M at book, would add to the value; both make the multiple higher, not lower.
- 2026-11-09editedre-struck on the 6 November close and the Q3 trailing figures; the multiple after pay in shares is added under the valuation rules
- 2026-11-10editedRe-struck at the 9 November close of $78.38 and the 10-Q's share count and debt
Where we disagree with the market
A growing outpatient imaging leader with AI on top; nine of 11 analysts rate it a buy.
The patients are real, but margins have not moved in years and growth reaches shareholders diluted.
Analysts expect earnings per share to nearly double in 2027. The filings show a loss over the past year after pay in shares and deal costs, margins flat near 16%, and 47% more shares since 2021.
Against us: growth is real and broad, the forecast has been raised twice this year, and a Medicare rule cutting hospital pay would send more patients its way.
What analysts say, and the evidence
The evidence under this - 6 claims
- 2026-11-09editedre-struck on the 6 November close with a fresh research pack
Adjusted EBITDA leaves out $59.3M of trailing stock pay, and partners' minority stakes, $298.0M at book, would add to the value; both make the multiple higher, not lower.
- 2026-11-09editedre-struck on the 6 November close and the Q3 trailing figures; the multiple after pay in shares is added under the valuation rules
- 2026-11-10editedRe-struck at the 9 November close of $78.38 and the 10-Q's share count and debt
- 2026-11-09editedQ3 2026 print replaces the Q2 figures
Q1 was cut by about $9M of adjusted EBITDA by weather (C33), so the full year needs a second half of $186M to $199M of imaging adjusted EBITDA, the strongest half the company has reported.
- 2026-11-09editedthird raise at Q3 2026 replaces the Q2 guidance
What could go wrong, and how we would know
The risks
- AI could lift margins. If AI drafts half of reports by mid-2027, as management plans, reading costs could fall and margins rise, which would make us wrong.
- Medicare could pay less. Medicare is about a quarter of revenue; management says the proposed 2027 rule costs under $1M, but the final rule is not out.
- Hospitals could compete harder. If hospitals cut prices or keep their higher rates, the flow of patients to cheaper centres could slow.
- A founder of 81. Berger has run the company since 1992 and his doctors' groups staff many centres; no successor is named.
- Salaries keep rising. Technologists and radiologists are scarce, and pay rose 6.8% at existing centres in Q2 2026.
The evidence under this - 6 claims
Imaging margins rose only 0.17 points in Q2 2026 despite a 2.4-point shift toward advanced scans; management blamed salary inflation and the cost of rolling out its own AI (C36).
- The rule text has not been read: management summarised it on the call, and the transcript's release date (14 November) falls after the call.
- Hospitals may seek a court or congressional delay; this thesis lists that as an open risk.
- 2026-11-10editedManagement said on the 9 November call that CMS finalised the site-neutral provision; the rule text itself is not yet read
The rule is a proposal; the final rule is due in November 2026, and RadNet's 10-K says rate cuts reduce revenue unless volumes or mix make up for them.
- 2026-11-10editedManagement priced the final rule on the 9 November call at about $5M of 2027 revenue, up from under $1M
What we still do not know
- What share of US scans is done outside hospitals, and how fast is it rising?
- How much does RadNet earn per scan against a hospital, insurer by insurer?
- How much of the software arm's revenue would stay if RadNet stopped buying from it?
- Does ONRAD earn the profit RadNet says, and how is the cash price paid for?
The evidence under this - 4 claims
No body publishes the outpatient share of scans by year, so the shift is inferred; part of the growth is new demand, such as prostate and amyloid PET scans, now over 25% of RadNet's PET volume.
Its same-centre margin barely moved in Q2 2026 (C04) and capitation revenue has fallen two years running (C02), neither what a widening scale advantage would show.
Imaging adjusted EBITDA margin is about 16%, so a business RadNet describes as earning about a third of its revenue as adjusted EBITDA is a different kind of profit pool, and the figure is unaudited and unchecked by any outside party.
What would change our view
- Unattractive→NeutralThe price falls back within 20% of fair value
It needs:
- ○The share price falls to about $7.82, back within 20% of what we think the business is worth.about ≈$13.69 today, 81% below the last close
- Unattractive→AttractiveThe price falls 20% under fair value
It needs:
- ○The share price falls to about $5.22, 80% of what we think the business is worth.about ≈$11.36 today, 84% below the last close
- Unattractive→NeutralMargins finally rise with growth intact
It needs all of:
- ○The imaging centres keep 17.5 cents of each revenue dollar as those earnings for a full year.checked at the next results, due by 2 Mar
- ○Scans of MRI, CT and PET at existing centres keep growing at least 8% a year.checked at the next results, due by 2 Mar
We would also be wrong if
- Cash after acquisitions pays for growth without new shares for two years.
- Medicare makes hospitals take the office price for simple scans from 2027.
What is coming
- 9 November 2026 Q3 2026 results: Whether the second half earns the $93M to $99M a quarter of imaging adjusted EBITDA the guidance needs, and whether the margin moves.
Every dated event ahead
- 9 November 2026 Q3 2026 results: Whether the second half earns the $93M to $99M a quarter of imaging adjusted EBITDA the guidance needs, and whether the margin moves.
- 30 November 2026 CMS final 2027 Medicare rules: Whether site-neutral pay for hospital imaging is finalised and whether RadNet's Medicare rates hold.
- 23 February 2027 ONRAD acquisition closes: Whether the deal closes on the stated terms and, with the ONRAD call, what its profit and the funding of the $350M cash look like.
- 15 August 2027 Q2 2027 results: Whether AI drafts half of reports and the imaging margin rises, as management targets.
Since we wrote this
- 11 NovThesis reviewUnattractive, high conviction: the view holds even in our best caseConviction re-graded on the new anchors: how robust the view is, not whether anything is still open.
- 10 NovEarningsCall read: Medicare cut small, site-neutral final; still UnattractiveThe final Medicare rule costs about $5M and management said hospitals lose site-neutral pay. The price is still more than twelve times our value near $6.37.
- 9 NovEarningsRevenue up 22% and guide raised again; margin barely moved, view holdsEarnings beat the quarter the last guide implied, but the margin rose 0.3 points and same-centre advanced scans slowed to 8.9%, so Unattractive holds.
- 9 NovThesis reviewStill Unattractive: priced at 1499% of a value near $5.07Re-valued in three stages at an 8% return, the method now drawn on every thesis: the price sits beyond the 20% margin of safety.
- 26 OctNewsRadNet agreed to buy teleradiology firm ONRAD$350M cash, 5M shares and an earn-out for a business RadNet says earns $60M to $65M a year; unchecked, so the view held.
- 11 OctThesis reviewDigital Health declared an early business, with a bet on itThe cheap-diagnosis Futures theory names RadNet for its AI reading tools, a segment that loses money and whose growth was mostly bought.
- 10 OctThesis writtenUnattractive, medium convictionWritten a month before Q3 results, after the shares recovered from a third lower in June on a second guidance raise.
Sources 27
Sources - 27
Every claim above cites one of these, or states the reasoning that derived it. The quote is frozen at the date it was read: a link can rot, and an agent fetch returns a reading of a page rather than the page. Backs counts the whole claim ledger, so it can name a claim this page does not surface.
- S01primarycompany filing2026-03-02centres and regions, payer revenue, competition classes, the consolidated medical group, risks, Digital Health clearances and customers, the equity offerings and iCADbacksC01C02C07C20C21C23C29C32C38C40
- S02primarycompany filing2026-08-10same-centre revenue and costs, acquisitions including Gleamer and the Idaho joint venture, debt, the segment note and AI deploymentbacksC05C08C09C11C22C26C31C35C36
- S03primarycompany release2026-08-09Q2 2026 results, volumes, Digital Health, payer mix, cash flow, net debt and revised 2026 guidancebacksC01C04C05C08C09C10C11C15C22C26C38C39
- S04primarycompany release2026-03-02full-year adjusted EBITDA, Q4 2025 results, payments and procedures by scan type, and the original 2026 guidancebacksC03C26
- S05primarytranscript2026-08-10RadNet Q2 2026 earnings call transcript (FMP), held 10 August 2026Digital Health's split and targets, the Medicare rule's effect, the hospital rule, the Florida acquisition, margin questions and net debt
Our analysis shows a negative impact of less than $1 million to 2027 revenue.
backsC11C12C15C31C32C36C38 - S06primarycompany release2026-06-10the $250M incremental term loan, the April 2031 maturity, the margin cut to SOFR plus 2.00% and the undrawn revolverbacksC09
- S07primarycompany filing2026-04-20the leaders, ownership, bonuses, share grants and the 2022 performance optionsbacksC29C30
- S08primarycompany filing2026-08-10five years and the trailing year of revenue, operating income, net income, cash flow, capital spending, stock pay and diluted sharesbacksC06C07C27C37
- S09primaryvendor data2026-10-09Research pack for RDNT (FMP market tier, FINRA short interest), fetched 10 October 2026the 9 October close, the 52-week range and returns, analyst ratings and estimates, the valuation series, short interest and the insider seriesbacksC25C26C27C28
- S10primaryregulator2026-07-07the proposal to pay off-campus hospital departments the office rate for imaging without contrast, and CMS's price comparisons
In 2025, this service had a physician office payment rate of around $30 and an OPPS payment rate of approximately $106, making the same scan more than three times as expensive in the OPD than in the physician office. ... Medicare paid 294 percent more in an OPD than in a freestanding office.
backsC13C22 - S11primaryindustry data2025-04-14Smith-Bindman et al., 'Projected Lifetime Cancer Risks From Current Computed Tomography Imaging', JAMA Internal Medicine, 2025 (PMC11997853) JAMA Internal Medicinethe national count of CT exams and patients in 2023 and the growth since 2007
An estimated 61 510 000 patients underwent 93 000 000 CT examinations in 2023 ... CT use is 30% higher today than in 2007
backsC16C22 - S12primaryregulator2026-10-10the count of AI-enabled devices by panel and year, and rival authorisations
The AI-Enabled Medical Device List is a resource intended to identify AI-enabled medical devices that are authorized for marketing in the United States.
backsC17 - S13primaryother2026-10-10SimonMed Imaging home page SimonMed Imaginga private rival's footprint and pitch
With 170+ locations across the US, it's easy to find a convenient location near you.
backsC18 - S14primarycompany filing2026-02-13a hospital group naming freestanding imaging centres among its competitionbacksC19
- S15primarycompany filing2026-02-05a scanner maker's AI software sold to cliniciansbacksC19
- S16primaryindustry data2024-03-21the projected physician shortage to 2036
the United States will face a physician shortage of up to 86,000 physicians by 2036.
backsC23 - S17primaryindustry data2025-02-04Hernström et al., MASAI randomised trial, The Lancet Digital Health, 2025 The Lancet Digital Healththe screen-reading workload saved by AI-supported mammography
resulting in a 44·2% reduction in the screen-reading workload
backsC24 - S18primaryregulator2026-07-16CMS, CY 2027 Physician Fee Schedule proposed rule (Federal Register, 16 July 2026, doc. 2026-14327) CMSthe proposed 2027 conversion factor
the 2027 nonqualifying APM conversion factor represents a projected decrease of $0.56 (-1.68 percent) from the current conversion factor of $33.5875.
backsC14 - S19primarycompany release2026-05-10Q1 2026 results, the weather effect and the first guidance raisebacksC26C33
- S20primarycompany filing2026-10-10each open-market sale, its price and its Rule 10b5-1 flagbacksC28
- S21primarycompany release2025-11-09Q3 2025 revenue, adjusted EBITDA and volumes, the baseline for Q3 2026backsC26C34C39
- S22primarycompany filing2026-10-26deal consideration, earn-out, closing conditions and timing
$350,000,000 in cash
backsC41 - S23primarycompany release2026-10-26what ONRAD does and the revenue and adjusted EBITDA RadNet expects it to add
ONRAD is expected to add $190 million to $200 million of Revenue and $60 million to $65 million of Adjusted EBITDA
backsC41C42 - S24primarycompany filing2026-11-09Q3 2026 revenue, adjusted EBITDA by segment, same-centre volumes, the guidance table after Q3, the balance sheet at 30 September 2026 and the adjusted EBITDA reconciliationbacksC04C05C09C10C39
- S25primarycompany filing2026-11-09trailing revenue, operating profit, stock pay, tax, debt, cash and the diluted share countbacksC44
- S26secondaryvendor data2026-11-09the analysts' average revenue and operating profit for the next three fiscal years, and the closebacksC43C44
- S27primarytranscript2026-11-09management's account of the quarter, the final 2027 Medicare and hospital outpatient rules, ONRAD's terms, Digital Health's annual recurring revenue and its fourth-quarter outlook, and how the guidance is raised
In the final rule, CMS finalized a deeper reduction to the conversion factor that it had proposed, a decrease of approximately 2.3% from $33.40 to $32.63. [...] finalized the site neutrality provision we discussed last quarter
backsC13C14C15C39C45